Essential thrombocythemia in a child: Management with anagrelide

Murali Chintagumpala, C. Philip Steuber, Donald H. Mahoney, Angela K. Ogden, Donald J. Fernbach

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Essential thrombocythemia (ET) is a rare disorder in children. An 11-year-old white boy was first seen in January 1986 with symptoms of abdominal pain. His platelet count was 1.5 million/mm3. Other hematological values and coagulation studies, including bleeding time, were normal. There was laboratory evidence of mild platelet dysfunction. Using the criteria of the Polycythemia Vera Study Group, a diagnosis of ET was made. He developed frequent headaches. Aspirin was prescribed for the next 2 years at varying doses and frequency. During this period, platelet counts ranged between 1 and 3 million/mm3. In view of progressive headaches and evidence of increasing platelet dysfunction, further treatment was indicated. The use of a new agent, anagrelide, reported effective in adults with ET, resulted in amelioration of symptoms and improvement in quantitative and qualitative platelet control with no significant untoward effects.

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalJournal of pediatric hematology/oncology
Issue number1
StatePublished - Jan 1 1991


  • Anagrelide
  • Essential thrombocythemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Essential thrombocythemia in a child: Management with anagrelide'. Together they form a unique fingerprint.

Cite this